Welcome to our dedicated page for SeaStar Medical Holding SEC filings (Ticker: ICUCW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SeaStar Medical Holding's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SeaStar Medical Holding's regulatory disclosures and financial reporting.
SeaStar Medical Holding Corp (ICU) reported that Chief Financial Officer Michael Messinger purchased 750 shares of Common Stock on August 18, 2026 in an open market or private transaction at $3.27 per share. Following this purchase, he directly owns 2,500 shares of SeaStar Medical common stock.
SeaStar Medical Holding Corporation reported continued early commercial progress but significant losses for the three and six months ended June 30, 2026. Net revenue was $615,000 in the quarter and $1.11 million year-to-date, up from $338,000 and $631,000 a year earlier, driven by increased adoption of its FDA-approved pediatric QUELIMMUNE therapy for acute kidney injury.
The company remains deeply loss-making. It recorded a net loss of $3.7 million for the quarter and $7.3 million for the first half of 2026, with operating expenses of $4.4 million in the quarter largely from research and development on its adult SCD program and general and administrative costs. Cash declined to $7.0 million at June 30, 2026, down from $12.0 million at year-end, and operating activities used $5.8 million of cash in the first half.
Management states that existing cash will not fund operations, including clinical trials, for 12 months and that this raises substantial doubt about the company’s ability to continue as a going concern. SeaStar is relying on equity financing facilities, including an at-the-market program and a standby equity purchase agreement, and has raised modest additional capital, while advancing pivotal adult AKI and other clinical studies on its SCD platform.
SeaStar Medical Holding Corporation reported second quarter 2026 results with strong revenue growth but widening losses. Net revenue for the three months ended June 30, 2026 was $0.615 million, up from $0.338 million in 2025, an 82% increase driven by growing adoption of QUELIMMUNE pediatric AKI therapy. Gross margin remained high at 91% on cost of goods sold of $54 thousand.
Operating expenses rose significantly as the company invested in its pipeline and commercialization. Research and development expense increased to $2.52 million from $1.04 million, primarily from higher clinical trial and personnel costs, while general and administrative expense rose to $1.83 million from $1.03 million. Net loss for the quarter widened to $3.73 million, or $0.91 per share, compared with a net loss of $2.00 million, or $1.77 per share, with weighted-average shares rising to 4.08 million.
Cash was $6.96 million as of June 30, 2026, down from $11.98 million at December 31, 2025, after using $5.76 million in operating cash during the first half of 2026. The company highlighted business progress including adding three top-rated children’s hospitals to the QUELIMMUNE customer base, advancing enrollment in the 339-patient NEUTRALIZE-AKI pivotal adult AKI trial, and obtaining ICD-10-PCS codes to support standardized inpatient billing for its SCD therapies.
Schlorff Eric reported acquisition or exercise transactions in this Form 4 filing.
SeaStar Medical Holding Corp Chief Executive Officer Eric Schlorff received an equity grant in the form of restricted stock units. The award covers 10,288 shares of common stock at a stated price of $0.00 per share, reflecting a compensation-related grant rather than an open-market purchase.
According to the filing, the restricted stock units will vest in three equal installments on July 1, 2026, November 1, 2026, and March 1, 2027. After this grant, Schlorff holds 50,140 shares of SeaStar Medical common stock directly.
Chung Kevin reported acquisition or exercise transactions in this Form 4 filing.
SeaStar Medical Holding Corp reported that Chief Medical Officer Kevin Chung received a grant of 7,202 shares of common stock in the form of restricted stock units. These RSUs were awarded at no cash cost to him as part of his compensation.
The award will vest in three equal installments on July 1, 2026, November 1, 2026, and March 1, 2027. After this grant, Chung directly holds 28,021 shares of SeaStar Medical common stock, showing his equity-based alignment with the company’s long-term performance.
Vincent Bernadette N reported acquisition or exercise transactions in this Form 4 filing.
SeaStar Medical Holding Corp director Bernadette N. Vincent reported an equity compensation grant on a Form 4. She received 4,000 shares in the form of restricted stock units that will vest in full on July 1, 2027. These units were awarded at a stated price of $0.00 per share, reflecting a compensation grant rather than a market purchase. After this award, her directly held common stock position increased to 8,200 shares, indicating a relatively small but notable addition to her ownership stake through long-term incentive compensation.
Neuman John reported acquisition or exercise transactions in this Form 4 filing.
SeaStar Medical Holding Corp director John Neuman received an equity award of 4,000 shares of common stock in the form of restricted stock units (RSUs). The award was granted at a price of $0.00 per share as compensation, not as an open-market purchase.
The RSUs will vest in full on July 1, 2027, meaning Neuman must remain eligible through that date to receive the underlying shares. Following this grant, he holds 16,200 shares of SeaStar Medical common stock in total as reported in this filing.
Van Heel Kenneth reported acquisition or exercise transactions in this Form 4 filing.
SeaStar Medical Holding Corp director Kenneth Van Heel received a grant of 4,000 restricted stock units. These RSUs vest in full on July 1, 2027, meaning he will receive the underlying shares if he remains eligible on that date. After this award, he directly holds 11,940 shares of common stock.
Baird Jennifer A reported acquisition or exercise transactions in this Form 4 filing.
SeaStar Medical Holding Corp director Jennifer A. Baird received an equity grant of 4,000 shares in the form of restricted stock units. These RSUs relate to common stock with a par value of $0.0001 per share and will vest in full on July 1, 2027.
After this award, Baird holds a total of 10,620 shares of SeaStar Medical common stock directly, reflecting her updated ownership position as reported in this Form 4 filing.
SeaStar Medical Holding Corporation approved cash and stock retention bonuses for executives Eric Schlorff and Kevin Chung under a 2026 Retention Bonus Program. Schlorff’s bonus totals $200,000 and Chung’s totals $140,000, each split into three equal installments.
Each one-third payment is scheduled for July 1, 2026, November 1, 2026, and March 1, 2027, subject to continued employment on each vesting date. Executives will also receive an additional amount equal to 25% of each payment in shares of common stock under the 2022 Omnibus Incentive Plan, based on the closing share price on each vesting date.
If an executive departs before a vesting date, remaining payments are forfeited, while a separation without cause provides a pro‑rated amount of the next payment. The company executed individual 2026 Retention Bonus Program Agreements with both executives, filed as exhibits to this report.